Epstein-Barr Virus Limits the Accumulation of IPO7, an Essential Gene Product

Ya-Chun Yang and Bill Sugden

McArdle Laboratory for Cancer Research, University of Wisconsin-Madison, Madison, WI, United States

Epstein-Barr virus (EBV) encodes more than 40 miRNAs that target cellular mRNAs to aid its infection, replication, and maintenance in individual cells and in its human host. Importin-7 (IPO7), also termed Imp7 or RanBPM7, is a nucleocytoplasmic transport protein that has been frequently identified as a target for two of these viral miRNAs. How the viral life cycle might benefit from regulating IPO7 has been unclear, though. We demonstrate with CRISPR-Cas9 mutagenesis that IPO7 is essential in at least three cells lines and that increasing its levels of expression inhibits growth of infected cells. EBV thus regulates the level of IPO7 to limit its accumulation consistent with its being required for survival of its host cell.

Keywords: epstein-barr virus, miRNAs, IPO7, EGR1, essential gene

INTRODUCTION

Epstein-Barr virus (EBV) is a human herpesvirus that is associated with several human cancers, including Burkitt’s lymphoma (BL), Hodgkin’s disease, post-transplant lymphoproliferative disease, and both gastric and nasopharyngeal carcinoma (NPC; Raab-Traub, 2002, 2015; Hammerschmidt and Sugden, 2004; Brady et al., 2007; Sugden, 2014; Tse and Kwong, 2015). Rather than only infecting replicating cells, EBV can infect quiescent B cells and drive them to proliferate. While EBV genomes are maintained as plasmids in these proliferating cells, defects in its DNA synthesis lead to its being lost from a population of proliferating cells unless it provides the cells that retain it sufficient selective advantages to outgrow those that lose it (Kennedy and Sugden, 2003; Nanbo et al., 2007; Vereide and Sugden, 2009). Multiple studies have shown that EBV’s miRNAs provide selective advantages early in infection of B-cells, in B-cell tumors, and in the switch from latency to the lytic phase of EBV’s life cycle (Feederle et al., 2011; Vereide et al., 2014; Albanese et al., 2016; Bernhardt et al., 2016; Tagawa et al., 2016; Chen et al., 2019). EBV encodes ~40 miRNAs, four of which are expressed from the BHRF locus, the remainder are expressed from the BART locus. These processed, mature miRNAs have been shown to regulate both cellular and viral functions (Cai et al., 2006; Barth et al., 2011; Marquitz et al., 2011, 2014; Cai et al., 2015; Kanda et al., 2015; Kang et al., 2015; Shinozaki-Ushiku et al., 2015; Zhang et al., 2018; Wang et al., 2019).
Multiple studies have identified the transcripts of IPO7 as common targets for EBV’s miRNAs including BART3 and BART16 (Riley et al., 2012; Skalsky et al., 2012; Vereide et al., 2014). These identifications have been supported by conditional assays and genetic analyses. For example, we have evicted EBV from Burkitt Lymphoma cells and found that their levels of the IPO7 protein increased. Re-expression of the viral miRNAs in these evicted cells decreased IPO7 to parental levels (Vereide et al., 2014). We have also infected primary B-cells with EBV and a derivative from which its miRNA genes were deleted and assayed the levels of IPO7 mRNAs. The absence of EBV’s miRNAs in newly infected B-cells led to a significant increase in the expression of IPO7 mRNA (Tagawa et al., 2016).

However, the selective advantages EBV gains by inhibiting IPO7 are unclear. IPO7, also called Imp7 or RanBPM7, is a nucleocytoplasmic transport protein that binds cargos in the cytoplasm, transports them through nuclear pore complexes (NPCs), and releases them in the nucleus upon binding to RanGTP (Görlich et al., 1997). IPO7 is an import factor for several proteins, including ribosomal proteins, histone H1, glucocorticoid receptor, Early growth response protein 1 (EGR1), HIV-1 integrase protein, NUP93, and SMAD4 (Jäkel and Görlich, 1998; Fassati et al., 2003; Freedman and Yamamoto, 2004; Ao et al., 2007; Chen et al., 2011; Kang et al., 2013; Braun et al., 2016). Inhibiting IPO7 decreases the nuclear import of some ribosomal proteins leading to the activation of cell death in some cells (Golomb et al., 2012). This finding might mean that EBV’s targeting IPO7 with its miRNAs inhibits survival of its transformed cells, a notion at odds with EBV’s known roles in transformation. We therefore sought to understand what advantages EBV gains by targeting IPO7. We found unexpectedly that IPO7 is an essential gene in an uninfected cell line and in both EBV-infected lymphoid and epithelial tumor cells. In addition, decreasing the expression of IPO7 in these cells did not affect their proliferation, while increasing it in EBV-positive gastric carcinoma cells inhibited their growth. These changes in the growth of the cells were paralleled by changes in IPO7’s activity as shown, for example, by the levels of EGR1 imported into the nucleus. EBV thus limits the level of IPO7 through its miRNAs to optimize the growth of transformed cells.

MATERIALS AND METHODS

Cell Lines
Epstein-Barr virus-positive SNU-719 cells, a gastric carcinoma-derived cell line (Oh et al., 2004), and 721 cells, a B-cell line transformed by EBV in vitro (Kavathas et al., 1980), were cultured in RPMI 1640 (Invitrogen) supplemented with L-glutamine, 10% fetal bovine serum (FBS), and antibiotics (200 U/ml penicillin and 200 μg/ml streptomycin). 293T cells were cultured in DMEM (Invitrogen) supplemented with L-glutamine, 10% FBS, and antibiotics (200 U/ml penicillin and 200 μg/ml streptomycin).

Plasmids
Plasmid 3051 was a retroviral vector that was constructed as described previously (Kennedy and Sugden, 2003). 3051-IPO7 was generated by cloning an IPO7 cDNA sequence into the NotI/BamHI sites of 3051. Plasmids pJWB1157 and pCEP-CRISPR that were used for generating CRISPR-Cas9-containing plasmids were kindly provided by Dr. Eric Johannsen (Department of Medicine, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, United States).

CRISPR-Cas9-Mediated Genome Editing

The targeting regions in IPO7 genomic DNA were predicted with the CRISPR Design Tool from the Zhang Lab (Hsu et al., 2013). The 20 n.t. spacer sequence followed by 3 n.t. PAM sequence (NGG) was inserted into the BbsI site of vector pJWB1157, which contains the Cas9 coding region and a U6-promoter regulated guide RNA. The cassette containing Cas9 and targeting sequence along with a guide RNA was digested with PciI/NotI and inserted into pCEP-CRISPR, which encodes EBNAl, OrIIP, and resistance to hygromycin. The plasmid pCEP-target-CRISPR was transfected into 293T, SNU719, or 721 cells, the cells selected with Hygromycin (200–500 μg/ml), clones isolated, and characterized via DNA sequencing.

Cell Transfection

293T and SNU-719 cells were transfected with different plasmid DNAs using Lipofectamine 2000 (Invitrogen) following the manufacturer’s instructions. About 721 cells were transfected by electroporation. The transfected cells were cultured for 2 days before any following analysis.

Cell Cloning

About 30, 100, 300, and 1,000 SNU-719 cells containing 3015 or 3015-IPO7 were seeded into 10 cm plates. After 1 month, the clones were counted, and the cloning frequency was calculated by dividing the number of surviving clones by the number of cells that had been seeded.

Western Blotting Analysis

About 5 × 10^6 cells were collected and lysed in RIPA buffer (50 mM Tris-HCl, pH 7.8, 50 mM NaCl, 5 mM EDTA, 0.5% Triton X-100, 0.5% NP-40) and Western blotting analysis was performed as described previously (Pratt et al., 2012). The blots were detected with mouse monoclonal anti-IPO7 (Sigma) directed to the C-terminus at 1:1,000 dilution, or mouse monoclonal anti alpha-tubulin (Sigma) at 1:10,000 dilution, followed by a secondary anti-mouse antibody (Promega) at 1:5,000 dilution.

Retroviral Transduction

The retroviruses were derived from a vesicular stomatitis virus G protein pseudotyped murine leukemia virus (Ory et al., 1996). Retrovirus was generated by transfecting 293T cells with 3 μg of a plasmid encoding the Gag-Pol element, 1 μg of a plasmid encoding the vesicular stomatitis virus G protein, 1 μg of plasmid encoding a derivative of nuclear factor-NFκB, and 10 μg of a plasmid carrying the retroviral backbone containing
either IPO7 or empty vector control using linear PEI reagent per 10 cm plate. Twenty-four hours post-transfection, the culture medium was changed with fresh DMEM supplemented with 50 mM HEPES. The supernatant was collected after 2–4 days post-transfection and filtered through a 0.45-micron filter. The virus particles were pelleted by centrifuging at 38,000 rpm for 3 h at 4°C and resuspending the pellet in 1/10 the initial volume of medium.

Flow Cytometry
About $1 \times 10^6$ SNU-719 cells transfected with 3051 or 3051-IPO7 were sorted, the total RNA was isolated using TRIzol (Ambion) according to the manufacturer's instructions and treated with DNase (QIAGEN) to remove contaminating DNA (Pratt et al., 2012). Around 300 ng of total RNA was reverse transcribed using AMV reverse transcriptase (Invitrogen) following the manufacturer's instructions. Real-time PCR was conducted as previously described (Pratt et al., 2009; Yang et al., 2017) and the relative mRNA quantity were determined by relative quantification using untreated SNU-719 mRNA to prepare standard curves, and then normalized to GAPDH. The following oligonucleotide sequences were used for real-time PCR (IDT): GAPDH (forward primer: TCAAGGACACTTTTGTCAAGCT, reverse primer: CCATGAGGTCTGCTGG), probe: TTCCTCGTATGACACCAAGGGCAAGAAC, BFP (forward primer: TGTGACAGGAGG, reverse primer: AGCAAGACTTAGTAAGAAG, probe: AATGAATGTTCCTGTCCGGTCTACAGGC, BLZF1 (forward primer: AGCTGTCTGTAGTCCAGTGGT, reverse primer: AGCGTTGACATGGTCCAGTGGT, probe: CTATGCTGATGGTGACATGGTCCAGTGC, CASP7 (forward primer: GTGGTTCTGTAGTGGCTACCATC, reverse primer: ATCGCAT, reverse primer: AGATTCAGTGGATGCTAAGCC, probe: TCTTCTGACAGTTGAAACGTA, prob: TCGCTGAGGTCTGCTGG), probe: TCATGCTGATGGTGACATGGTCCAGTGGT, probe: TCTTCTGACAGTTGAAACGTA, prob: TCGCTGAGGTCTGCTGG), probe: TCATGCTGATGGTGACATGGTCCAGTGGT, probe: TCTTCTGACAGTTGAAACGTA, probe: TCGCTGAGGTCTGCTGG).

Immunofluorescent Detection of EGR1 Nuclear Translocation
About $1 \times 10^6$ SNU-719 cells transfected with 3051 or 3051-IPO7 were collected and washed with PBS. The cells were fixed in 4% paraformaldehyde (PFA) for 10 min, washed, permeabilized with 0.05% triton X, and incubated for 20 min with 1% BSA. The cells were further incubated with rabbit anti-EGR1 monoclonal antibody (1:200; Cell Signaling) in PBS containing 1% BSA for 40 min. After washing with PBS, the cells were incubated for 20 min with 0.2 µg PE-conjugated donkey anti-rabbit IgG (Bio Legend) in 200 µl of PBS/1% BSA. The cells were then washed with PBS and resuspended in 50 µl of PBS/2% FBS with Draq5 (1:2,000; Bio Legend) for 5 min and run directly on the ImageStream Mark II (Amnis).

ImageStream Data Acquisition and Analysis
The fluorescence image-based method for quantifying nuclear translocation was described previously (George et al., 2006). The degree of nuclear translocation can be measured by a similarity score that compares a cell's nuclear fluorescence image to the pattern of fluorescence produced by the EGR1 signal. A high positive value of a similarity score would indicate that the signal from EGR1 and the corresponding nuclear image are similar. The similarity score is derived from Pearson's correlation coefficient ($\rho$) that has been validated previously (George et al., 2006). Briefly, the formula of the PCC is denoted as:

$$\rho = \frac{\sum (x_i - \bar{x})(y_i - \bar{y})}{\sqrt{\sum (x_i - \bar{x})^2 (y_i - \bar{y})^2}}$$

where $x_i$, $y_i$ are the pre-pixel intensity values of the two images at the same location, and $X$, $Y$ are the corresponding mean intensity values. In this study, the data sources are the nuclear and EGR1 fluorescence images of the same cell.

The similarity score transforms the PCC to a log scale to improve the discrimination, which was denoted as:

$$\text{Similarity} = \ln \frac{1 + \rho}{1 - \rho}$$

Reverse Transcription and Real-Time PCR
SNU-719 cells transfected with 3051 or 3051-IPO7 were sorted, and the signal from EGR1 and the corresponding nuclear image are similar. The similarity score that compares a cell's nuclear fluorescence image to the pattern of fluorescence produced by the EGR1 signal. A high positive value of a similarity score would indicate that the signal from EGR1 and the corresponding nuclear image are similar. The similarity score is derived from Pearson's correlation coefficient ($\rho$) that has been validated previously (George et al., 2006). Briefly, the formula of the PCC is denoted as:

$$\rho = \frac{\sum (x_i - \bar{x})(y_i - \bar{y})}{\sqrt{\sum (x_i - \bar{x})^2 (y_i - \bar{y})^2}}$$

where $x_i$, $y_i$ are the pre-pixel intensity values of the two images at the same location, and $X$, $Y$ are the corresponding mean intensity values. In this study, the data sources are the nuclear and EGR1 fluorescence images of the same cell.

RESULTS
Both Alleles of IPO7 Could Not Be Deleted From Human Cell Lines
To elucidate any selective advantages EBV is afforded by inhibiting IPO7 in infected cells, we used CRISPR-Cas9-mediated genome editing to target the IPO7 gene in human cell lines with the goal of eventually expressing IPO7 conditionally. We used this approach also to avoid the off-targeting inherent to assays with siRNAs. While siRNAs recognize a desired target with perfect complementarity, they act through the miRNA pathway so that the “seed sequences” they necessarily encode direct them to other mRNAs, their “off-targets.” Such “off-targets” can be more robustly recognized
that the desired target (Riba et al., 2017; Smith et al., 2017). Cas9 and guide RNAs targeting nucleotides 172–191 and 25,342–25,361 n.t., respectively, of IPO7 (Figure 1) were expressed with a stably replicating plasmid vector in 293T cells, which are EBV-negative, and two EBV-positive cell lines, 721 and SNU-719. Multiple clones were selected, and Sanger sequencing was performed to determine the editing of the targeted sites. Among 12 293T clones, five clones had no detected genomic changes in either allele; two of the remaining clones had a single mutated allele. These mutations were in-frame (e1#1), or frame-shifted with ten nucleotides deleted (e1#7). The remaining five clones had mutations in both alleles. One clone had an in-frame deletion of three nucleotides and an allele with a frame-shift mutation consisting of a deletion of 34 nucleotides (e1#2). The other four clones had each allele with in-frame mutations with deletions or insertions (clones e1#6, e1#8, e4#6, and e4#9; Figure 2; Table 1). We assayed the levels of expression of IPO7 in these clones. All of these clones expressed detectable but variable levels of IPO7 (Figure 2C) as did an additional four clones, e1#4, e1#5, e4#8, e4#11, in which the sequences of mutated alleles could not be determined. Thus in nine clones of EBV-negative, 293T cells, in which one or both alleles of IPO7 were successfully mutagenized, all expressed the protein detectably. This CRISPR-based method has been used successfully with analogous results to identify essential genes in other organisms (You et al., 2020).
We conclude therefore that IPO7 is essential for the growth and survival of 293T-cells in culture.

The same approach was used to mutagenize IPO7 in two EBV-positive cells, 721, a B-cell line and SNU-719, a gastric carcinoma cell line. Among 24 clones of 721 cells amenable to sequencing, two lacked genomic changes in each allele; two clones contained one wild-type allele and one allele with an in-frame mutation; and 12 clones contained one allele with an in-frame mutation and one allele with a frame-shift mutation; and eight clones had both alleles with in-frame mutations (Figure 3; Table 1). All of these clones were read through sequencing and the mutated genomic sequence and amino acids are shown in blue. The IPO7 expression of certain IPO7 mutants decreased as detected via Western blotting. The expression of α-Tubulin was measured as an internal control. The mean intensity of IPO7 in these clones was 0.31 relative to the control with a S.E. ±0.14.

![FIGURE 2](image_url) CRISPR-engineered IPO7-mutants in 293T cells. 293T cells were transfected with guide RNAs that targeted exon1 (A), or exon4 (B) along with Cas9, and selected with Hygromycin for 3 weeks. The wild-type sequence is shown; the target sequence is shown in red and PAM underlined and shown in green. The sequence of each clone was read through sequencing and the mutated genomic sequence and amino acids are shown in blue. (C) The IPO7 expression of certain IPO7 mutants decreased as detected via Western blotting. The expression of α-Tubulin was measured as an internal control. The mean intensity of IPO7 in these clones was 0.31 relative to the control with a S.E. ±0.14.
allele; two contained one wild-type allele and one allele with
an in-frame mutation; one clone had one wild-type allele and
one with a frame-shift mutation; 10 clones contained one allele
with an in-frame mutation and one with a frame-shift mutation;
and nine clones had two in-frame mutated alleles (Figure 4;
Table 1). The IPO7 was examined by Western blotting, and
some of these clones expressed IPO7 at lower levels than did
cells with two wild-type alleles (Figure 4C). For two clones
of SNU719 cells, clone e4#1 and e4#6, in which the sequences
of mutated IPO7 could not be determined, IPO7 was still
detected in a Western blot (Figure 4C). In the 28 characterized
mutant derivatives of SNU-719 cells, all expressed IPO7 detectably
indicating that some level of expressed IPO7 protein is essential
for the growth and or survival of these cells.

One additional approach to testing if IPO7 is an essential
gene in these cell lines is to determine the likelihood for the
observed distribution of mutations in the 44 clones having
mutations in both alleles (Table 1) arising by chance. In a
simple, conservative model, in-frame mutations arise in one
out of three contiguous deletions and out-of-frame deletions
arise in two out of three of them. We used a permutation
test to ask, given 88 alleles, of which 65 are in-frame and 23
are frame-shifted, if we randomly compute pairs over and over
again, what is the fraction of the times in which frameshifts
occur in both alleles? While we observed no such double
frameshift, the permutation test predicted 1.9% would be double
frameshifts yielding a value of $p = 0.019$. Again, we conclude
that IPO7 is an essential gene in these three cell lines.

### Increasing Expression of IPO7 Inhibited the
Cloning Efficiency of EBV-Positive Cells

Having found that IPO7 is essential for 293T cells and for
EBV-positive cells, we asked if its increased expression was
beneficial to one of the EBV-positive cells, SNU-719 cells,
which are adherent and readily manipulated in culture. SNU-719
cells were infected with a retrovirus that expresses a bicistronic
IPO7-IRES-GFP cassette, the infected cells were collected by
sorting those with different levels of GFP, and further analyzed
by cloning. SNU-719 cells with varied levels of IPO7 expressed
from this vector had decreased efficiencies of cloning relative
to SNU-719 cells infected with the empty vector (Figure 5A).
We confirmed this finding with bulk populations of retrovirus-
infected cells by picking clones of infected cells and testing
their cloning efficiencies. A clone infected with the retrovirus
that expressed IPO7 at a 3-fold higher level than a clone
infected with the empty virus had 40-fold lower cloning efficiency
(Figure 5B). We also tested if a decreased expression of IPO7
affected the survival of these cells. The cloning efficiency of
one IPO7-CRISPR mutant, SNU719 e4#4, was determined and
compared with that of a wild-type clone. SNU719 e4#4 had
a lower expression of IPO7 (Figure 4C) and gave the same
cloning efficiency as that of wild-type cells (Figure 5C).

Increasing the expression of IPO7 modestly in a bulk
population of SNU-719 cells diminished their cloning; increasing
it several fold inhibited cloning of these cells dramatically
(Figures 5A,B). These findings are complemented by the findings
with the EBV-positive 721 cells in which four clones with
decreased levels of IPO7 were found to clone as efficiently as
did the parental cell. While IPO7 is essential for EBV-positive
cells, lower than wild-type levels of expression are tolerated,
but higher than wild-type levels are deleterious to their growth
and/or survival.

### IPO7 Causes the Accumulation of EGR1 in
the Nucleus

Previous studies found that IPO7 is critical for the translocation
of EGR1 into the nucleus (Fassati et al., 2003; Ao et al., 2007).
The expression of EGR1 increases when EBV's lytic phase is
induced by treating B-cells with anti-immunoglobulin (Ye et al.,
2010) and its transcription is increased by EBV's early gene,
BZLF1, which also fosters the induction of EBV's lytic phase
(Chang et al., 2006; Heather et al., 2009). It is therefore
reasonable to hypothesize that the regulation of IPO7 in turn
regulates the level of EGR1, which is one determinant of the
EBV's entry into its lytic phase. We tested this hypothesis by
measuring the localization of EGR1 to the nucleus in cells
expressing different levels of IPO7 and the effects of this nuclear
localization on genes regulated by EGR1. To do so, SNU-719
cells were transfected with an empty retroviral vector, 3051,
or 3051 expressing IPO7 and the degree of nuclear translocation
of EGR1 was measured by ImageStream. This approach allowed
us to assay a thousand immunochemically stained cells and
a thousand control cells. Localization of the immunochemically
stained EGR1 to the nucleus is reflected by the "similarity
score" (George et al., 2006). A higher positive value of the
similarity score means that the florescent signal of EGR1 and
the nuclear image are more alike, indicating that more EGR1
is localized to the nucleus. The measurements showed that a
greater portion of EGR1 distributed to the nucleus and exhibited
a similarity score greater than 2 in SNU-719 cells that expressed
3051-IPO7 relative to these cells with the empty vector
(Figures 6A,B). When cells overexpressing IPO7 were compared
to those expressing the empty vector, 2.6-fold more EGR1 was
localized to the nuclei and these cells exhibited a similarity
score $> 4$. The measurement of EGR1's movement to the nucleus
with high levels of IPO7 is robust as reflected by similar

| Table 1 | CRISPR-engineered mutations in IPO-7 and allele classifications. |
|--------|---------------------|---------------------|---------------------|---------------------|---------------------|
| Cell type | WT | WT/Inframe mut | WT/Frameshift mut | Inframe mut/Frameshift mut | Inframe mut/Inframe mut | Total |
| 293T | 5 | 1 | 1 | 1 | 4 | 12 |
| 721 | 2 | 2 | 0 | 12 | 8 | 24 |
| SNU-719 | 4 | 2 | 1 | 10 | 9 | 26 |
| Total | 11 | 5 | 2 | 23 | 21 | 62 |
measurements of IkBα with or without its nuclear localization sequence localizing to the nucleus. This assay found less than a 2-fold difference in the similarity score for these two conditions (Lisiero et al., 2020). Increasing expression of IPO7 thus contributes to increasing nuclear localization of EGR1.

To determine if increased nuclear localization of EGR1 leads to changes in the expression of genes it regulates in EBV-positive cells, we considered candidates identified previously by ChIP-on-ChIP assays performed in prostate tumor cells (Arora et al., 2008). EGR1 can enhance the transcription of a gene's promoter directly or inhibit a gene's expression indirectly, for example, by enhancing expression of specific miRNAs (Xu et al., 2015). We screened the candidates for ones differentially expressed in B-cells transformed with a wild-type strain of EBV vs. B-cells transformed by a strain of EBV deleted for its miRNAs (Tagawa et al., 2016) to focus on candidates potentially affected by differing levels of expression of IPO7. We then assayed some of these candidates in SNU-719 cells transfected with the empty vector, 3051, or the vector expressing IPO7, 3051-IPO7. Three of these genes, Protein Tyrosine Phosphatase Receptor Type O (PTPRO), a member of the transmembrane receptor family of protein tyrosine phosphatases (Motiwala et al., 2003, 2004; You et al., 2012), basic leucine zipper nuclear factor 1 (BLZF1; Tong et al., 2000), and Bcl-2 modifying factor (BMF; Frenzel et al., 2010; Baumgartner et al., 2013) were altered in their expression with PTPRO decreasing and both BLZF1 and BMF increasing by a factor of 2 (Figure 6C). The levels of two other candidates, Caspase 7 and Major Vault Protein, were not altered between these cells (Figure 6C). Although it is unclear whether the changes in expression of BLZF1, BMF, and PTPRO contribute to the deleterious effects in EBV-positive cells when levels of IPO7 are increased, increasing the level of IPO7 increases the level of EGR1 transported into nucleus without increasing the accumulation of its RNA (Figure 6C). The resulting increases in the nuclear localization of EGR1 correlate with significant changes in the levels of some genes that are candidates for being regulated by EGR1 in EBV-positive cells indicating that not only is more EGR1 moving to the nucleus but also appears to be regulating transcription there, too.

We independently confirmed this coupled analysis of ImageStream and mRNA measurements of EGR1 transcriptional targets. We assessed the levels of the RNAs encoding the relevant genes in cells infected with wild-type EBV or with a mutant lacking its miRNA genes (Tagawa et al., 2016). In the cells infected with wild-type EBV and its miRNAs, IPO7 was detected in the RISC complex and was reduced significantly to 0.82 of wild-type levels. In the presence of EBV's miRNAs, EGR1 mRNA levels remained the same but the levels of its two transcriptional
targets, BMF and BLZF1, were decreased significantly to 0.75 and 0.81 of the levels measured in the absence of the miRNAs, respectively. These two mRNAs were not detected in the RISC complex consistent with their decreased levels resulting from less EGR1 being transported into the nucleus by IPO7.

**DISCUSSION**

Several large-scale screens have found the transcripts of IPO7 to be frequent targets for EBV’s miRNAs including BART3 and BART16 (Riley et al., 2012; Skalsky et al., 2012; Vereide et al., 2014). Multiple studies have also found that EBV’s targeting specific cellular RNAs with its miRNAs provides EBV selective advantages by, for example, avoiding apoptosis or evading a host’s immune responses (Marquitz et al., 2011, 2012, 2014; Riley et al., 2012; Vereide et al., 2014; Cai et al., 2015; Kanda et al., 2015; Kang et al., 2015; Lin et al., 2015; Shinozaki-Ushiku et al., 2015; Albanese et al., 2016; Tagawa et al., 2016; Zhang et al., 2018; Murer et al., 2019; Wang et al., 2019). We have asked if EBV’s targeting IPO7 provides EBV-infected cells a selective advantage, and if so, what that advantage might be. Because IPO7 contributes to the nuclear import of many proteins (Pumroy and Cingolani, 2015), it is unlikely that any possible advantage gained by targeting IPO7 can be ascribed to only one of IPO7’s cargoes. In addition, several different importins often transport the same protein into the nucleus (Pumroy and Cingolani, 2015) possibly confounding our identifying any advantage EBV derives from targeting IPO7. We first attempted to delete the IPO7 gene from the EBV-negative 293T cell line, from an EBV-positive B-cell line, 721, and from an EBV-positive gastric carcinoma cell line, SNU-719 using CRISPR/Cas9. We found that among 44 clones with mutations in both alleles of IPO7 in these three cell types (Table 1) all expressed IPO7 detectably indicating that IPO7 is an essential gene in these cells. This conclusion is supported by a permutation test in which we randomly computed pairs of alleles over and over again and asked what is the fraction of the times in which frameshifts occur in both alleles based on our experimental finding of 23 of 88 alleles with frameshifts? While we observed no such double frameshift, the permutation test predicted 1.9% would be double frameshifts yielding a value of $p = 0.019$. It is surprising, perhaps, that EBV uses its miRNAs to target the mRNAs of an essential gene. However, EBV’s targeting IPO7 is substantiated by two sets of functional analyses: First, evicting EBV from Burkitt Lymphoma cells leads to their levels of the IPO7 protein being increased, while re-expression of the viral miRNAs in these evicted cells leads to IPO7 being decreased to parental.
Yang and Sugden
EBV Regulates Accumulation of IPO7

levels (Vereide et al., 2014). Second, infecting primary B-cells with EBV or a derivative from which its miRNA genes were deleted shows that the absence of EBV’s miRNAs in newly infected B-cells leads to a significant increase in the expression of IPO7 mRNA (Tagawa et al., 2016).

Inhibiting IPO7 reduces the nuclear import of some ribosomal proteins, leads to the activation of p53 and decreases the survival of some cell types (Golomb et al., 2012). We measured the survival of EBV-positive B-cells and EBV-positive gastric carcinoma cells in which the levels of IPO7 were demonstrably reduced following mutagenesis by treatment with CRISPR/Cas9 (Figures 3C, 4C) and found no effect on their survival. Given that in these experiments, the levels of IPO7 were often decreased relative to those in the parental EBV-positive cells, we can conclude that the levels of IPO7 achieved by EBV’s miRNAs in these lymphoid and epithelial cells do not activate p53 to promote cell death. cMyc stimulates the expression of IPO7 (Golomb et al., 2012) and EBV genes can regulate the expression of cMyc. For example, the conditional expression of the LMP-1 gene of EBV in B-cells induces the expression of cMyc (Dirmeier et al., 2005). Perhaps, EBV-transformed lymphoid and epithelial cell lines use multiple paths to ensure that the expression of IPO7 is consistent with their survival. Given that EBV-transformed cells can accommodate decreased levels of IPO7, we asked if they could also accommodate increases in its expression. A vector expressing IPO7 or an empty vector was introduced into SNU-719 cells and populations or clones of these cells were tested for their survival by measuring the efficiencies of their cloning. The added IPO7 functioned in these cells. The increased levels of IPO7 increased the nuclear import of its cargo as measured by the increased nuclear localization of EGR1 and alterations in the expression of some genes known to be regulated by EGR1 (Figure 6). These increases in IPO7 inhibited the cloning efficiencies of both the bulk populations of cells and a clone of them (Figure 5) thus limiting proliferation. We conclude that EBV targets IPO7.
Yang and Sugden

EBV Regulates Accumulation of IPO7

with its miRNAs to cap the expression of IPO7 at a level optimal for the growth of EBV-transformed cells.

DATA AVAILABILITY STATEMENT

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/supplementary material.

AUTHOR CONTRIBUTIONS

Y-CY and BS designed experiments, interpreted data, and wrote the manuscript. Y-CY performed experiments. All authors contributed to the article and approved the submitted version.

FUNDING

This work was supported by grants from the National Institutes of Health (Grants P01 CA022443). BS is an American Cancer Society Research Professor.

ACKNOWLEDGMENTS

We thank Adityarup Chakravorty and Mitch Hayes, for their helpful insights, comments, and suggestions. We also thank Mitch Hayes for his substantive contributions in revising this manuscript, Eric Johannsen for his help with pCEP-CRISPR, and Lauren and Arthur Sugden for their help with the permutation tests.

FIGURE 6 | The nuclear accumulation of EGR1 in SNU-719 cells with high level IPO7 expression. (A) SNU-719 cells transfected with 3051 or 3051-IPO7 were fixed and stained for EGR1 and with Draq5 (Draq5 is a nuclear stain that tags its localization). The cell suspensions were run on ImageStream. Brightfield (white), EGR1 (green), Draq5 (red), and EGR1/Draq5 composite images for three representative cells (of 1,000 imaged) are shown for each transfection sample. (B) The EGR1/Draq5 similarity score from 1,000 images of each transfection sample were analyzed by ImageStream and depicted in the histogram. The percentage of cells that fall within a High Similarity region are drawn. (C) SNU-719 cells transfected with 3051 or 3051-IPO7 were sorted based on their EGFP signal intensities. Total RNAs were isolated and reverse transcribed. The transcript levels of the EGR1-regulated genes, including BLZF1, BMF, PTPRO, CASP7, and MVP were measured with quantitative PCR. The transcript level of EGR1 was also measured. The transcript level of IPO7 was measured to confirm the overexpression of IPO7. The error bars indicated the SD. *p values were calculated by Student’s t test. *p < 0.05; **p < 0.001.
REFERENCES

Albanese, M., Tagawa, T., Bouvet, M., Maliqi, L., Lutter, D., Hoser, I., et al. (2016). Epstein-Barr virus microRNAs reduce immune surveillance by virus-specific CD8+ T cells. Proc. Natl. Acad. Sci. U. S. A. 113, E6467–E6475. doi: 10.1073/pnas.1605884113

Au, Z., Huang, G., Yao, H., Xu, Z., Labine, M., Cochran, A. W., et al. (2007). Interaction of human immunodeficiency virus type 1 integrase with cellular nuclear import receptor importin 7 and its impact on viral replication. J. Biol. Chem. 282, 13456–13467. doi: 10.1074/jbc.M705462000

Arora, S., Wang, Y., Jia, Z., Vardar-Sengul, S., Munawar, A., Doctor, K. S., et al. (2008). Egr1 regulates the coordinated expression of numerous EGF receptor target genes as identified by ChIP-on-chip. Genome Biol. 9:R166. doi:10.1186/gb-2008-9-11-r166

Barth, S., Meister, G., and Grasser, F. A. (2011). EBV-encoded miRNAs. Biochim. Biophys. Acta 1809, 631–640. doi: 10.1016/j.bbagrm.2011.05.010

Baumgartner, F., Weoss, C., Pedit, V., Tzanok, A., Labi, V., and Villunger, A. (2013). Minor cell-death defects but reduced tumor latency in mice lacking the BH3-only proteins Bad and Bmf. Oncogene 32, 621–630. doi: 10.1038/ onc.2012.78

Bernhardt, K., Haar, J., Tsai, M. H., Poirey, R., Feederle, R., and Deleusse, H. J. (2016). A viral microRNA cluster regulates the expression of Pten, p27 and of a beta-catenin homolog. PLoS Pathog. 12:e1005405. doi: 10.1371/journal.ppat.1005405

Brady, G., MacArthur, G. J., and Farrell, P. J. (2007). Epstein-barr virus and Burkitt's lymphoma. J. Clin. Pathol. 60, 1397–1402. doi: 10.1111/j.1365-2776.2007.0079777

Braun, D. A., Sadowski, C. E., Kohl, S., Lovric, S., Aistradis, S. A., Pabst, W. L., et al. (2016). Mutations in nuclear pore complex NUP93, NUP205 and XPO5 cause steroid-resistant nephrotic syndrome. Nat. Genet. 48, 457–465. doi: 10.1038/ng.3512

Cai, L. M., Lyu, X. M., Luo, W. R., Cui, X. F., Ye, Y. F., Yuan, C. C., et al. (2015). EBV-miR-BART7-3p promotes the EMT and metastasis of nasopharyngeal carcinoma cells by suppressing the tumor suppressor PTEN. Oncogene 34, 2156–2166. doi: 10.1038/onc.2014.341

Cai, X., Schaefer, A., Lu, S., Bilello, J. P., Desrosiers, R. C., Edwards, R., et al. (2006). Epstein-barr virus microRNAs are evolutionarily conserved and differentially expressed. PLoS Pathog. 2:e23. doi: 10.1371/journal.ppat.0020023

Chang, Y., Lee, H. H., Chen, Y. T., Lu, J., Wu, S. Y., Chen, C. W., et al. (2006). Induction of the early growth response 1 gene by Epstein-barr virus lytic transactivator Zta. J. Virol. 80, 7748–7755. doi: 10.1128/jvi.2006-0508

Chen, Y., Facho, D., Ivanov, N. S., Skinner, C. M., and Skalsky, R. L. (2019). Epstein-barr virus microRNAs regulate B cell receptor signal transduction and lytic reaction. PLoS Pathog. 15:e1007535. doi: 10.1371/journal.ppat.1007535

Chen, J., Liu, M. Y., Parish, C. R., Chong, B. H., and Khachigian, L. (2011). Nuclear import of early growth response-1 involves importin-7 and the novel nuclear localization signal serine-proline-serine. Int. J. Biochem. Cell Biol. 43, 905–912. doi: 10.1016/j.biocel.2011.03.004

Dirrmeier, U., Hoffmann, R., Kilger, E., Schulteiss, U., Brisen, C., Gires, O., et al. (2005). Latent membrane protein 1 of Epstein-barr virus coordinately regulates proliferation with control of apoptosis. Oncogene 24, 1711–1717. doi: 10.1038/sj.onc.1208367

Fassati, A., Görlich, D., Harrison, I., Zaytseva, L., and Motiwala, T. (2012). Viral microRNA cluster strongly potentiates the transforming activity of EBV-encoded miRNA cluster of the M81 strain modules multiple functions in primary B cells. PLoS Pathog. 11:e1005344. doi: 10.1371/journal.ppat.1005344

Lisiero, D. N., Cheng, Z., Tejera, M. M., Neldner, B. T., Warrick, J. W., Wuerzberger-Davis, S. M., et al. (2020). IκBα nuclear export enables 4-1BB-induced cRel activation and IL-2 production to promote CD8 T cell immunity. J. Immunol. 205, 1540–1553. doi: 10.4049/jimmunol.2000039

Lyu, X., Wang, J., Guo, X., Wu, G., Jiao, Y., Faleati, O. D., et al. (2018). EBV-miR-BART1-5P activates AMPK/HIF1 pathway via a PTEN independent manner to promote glycolysis and angiogenesis in nasopharyngeal carcinoma. PLoS Pathog. 14:e1007484. doi: 10.1371/journal.ppat.1007484

Marquitz, A. R., Mathur, A., Chugh, P. E., Dittmer, D. P., and Raab-Traub, N. (2014). Expression profile of microRNAs in Epstein-barr virus-infected AGS gastric carcinoma cells. J. Virol. 88, 1389–1393. doi: 10.1128/jvi.02662-13

Marquitz, A. R., Mathur, A., Nam, C. S., and Raab-Traub, N. (2011). The Epstein-barr virus BART microRNAs target the pro-apoptotic protein Bim. Virology 420, 392–400. doi: 10.1016/j.virol.2011.01.028

Marquitz, A. R., Mathur, A., Shair, K. H., and Raab-Traub, N. (2012). Infection of Epstein-barr virus in a gastric carcinoma cell line induces anchorage independence and global changes in gene expression. Proc. Natl. Acad. Sci. U. S. A. 109, 5939–5938. doi: 10.1073/pnas.1202910109

Motiwala, T., Ghoshal, K., Das, A., Majumder, S., Weichenhan, D., Wu, Y. Z., et al. (2003). Suppression of the protein tyrosine phosphatase receptor type O gene (PTPRO) by methylation in hematopoietic cell lines. Oncogene 22, 6319–6331. doi: 10.1038/sj.onc.1206750

Motiwala, T., Kutay, H., Ghoshal, K., Bai, S., Seimiya, H., Tsuruo, T., et al. (2004). Protein tyrosine phosphatase receptor-type O (PTPRO) exhibits characteristics of a candidate tumor suppressor in human lung cancer. Proc. Natl. Acad. Sci. U. S. A. 101, 13844–13849. doi: 10.1073/pnas.0405451101

Yang and Sugden EBV Regulates Accumulation of IPO7
Murer, A., Rühl, J., Zbinden, A., Capaul, R., Hammerschmidt, W., Chijioke, O., et al. (2019). MicroRNAs of Epstein-Barr virus attenuate T-cell-mediated immune control in vivo. mBio 10, e01941–e02018. doi: 10.1128/mBio.01941-18

Nano, A., Sugden, A., and Sugden, B. (2007). The coupling of synthesis and partitioning of EBV’s plasmid replicon is revealed in live cells. EMBO J. 26, 4252–4262. doi: 10.1038/sj.emboj.7601853

Oh, S. T., Seo, J. S., Moon, U. Y., Kang, K. H., Shin, D. J., Yoon, S. K., et al. (2004). A naturally derived gastric cancer cell line shows latency 1 Epstein-Barr virus infection closely resembling EBV-associated gastric cancer. Virology 330, 330–336. doi: 10.1016/j.virol.2003.12.005

Ory, D. S., Neugeboren, B. A., and Mulligan, R. C. (1996). A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes. Proc. Natl. Acad. Sci. U. S. A. 93, 11400–11406. doi: 10.1073/pnas.93.21.11400

Pfeffer, S., Zavolan, M., Grasser, F. A., Chien, M., Russo, J. I., Ju, J., et al. (2004). Identification of virus-encoded microRNAs. Science 304, 734–736. doi: 10.1126/science.1096781

Pratt, Z. L., Kuzembayeva, M., Sengupta, S., and Sugden, B. (2009). The microRNAs of Epstein-Barr virus are expressed at dramatically differing levels among cell lines. Virology 386, 387–397. doi: 10.1016/j.virol.2009.01.006

Pratt, Z. L., Zhang, J., and Sugden, B. (2012). The latent membrane protein 1 (LMP1) oncogene of Epstein-Barr virus can simultaneously induce and inhibit apoptosis in B cells. J. Virol. 86, 4380–4393. doi: 10.1128/jvi.00696-11

Pumroy, R. A., and Cingolani, G. (2015). Diversification of importin-α isoforms in cellular trafficking and disease states. Biochem. J. 466, 13–28. doi: 10.1042/bj20141186

Raab-Traub, N. (2002). Epstein-Barr virus in the pathogenesis of NPC. Semin. Cancer Biol. 12, 431–441. doi: 10.1016/S1044579X(02)00086-X

Raab-Traub, N. (2015). Nasopharyngeal carcinoma: an evolving role for the Epstein-Barr virus. Curr. Top. Microbiol. Immunol. 390, 339–363. doi: 10.1007/978-3-319-22822-8_14

Riba, A., Emmenlauer, M., Chen, A., Sigouillot, F., Cong, F., Dehio, C., et al. (2017). Explicit modeling of siRNA-dependent on- and off-target repression improves the interpretation of screening results. Cell Syst. 4, 182.e4–193.e4. doi: 10.1016/j.cels.2017.01.011

Riley, K. J., Rabinowitz, G. S., Varios, T. A., Luna, J. M., Darnell, R. B., and Steitz, J. A. (2012). EBV and human microRNAs co-target oncogenic and apoptotic viral and human genes during latency. EMBO J. 31, 2207–2221. doi: 10.1038/emboj.2012.63

Shinozaki-Ushiku, A., Kunita, A., Isogai, M., Hibiya, T., Ushiku, T., Takada, K., et al. (2015). Profiling of virus-encoded microRNAs in Epstein-Barr virus-associated gastric carcinoma and their roles in gastric carcinogenesis. J. Virol. 89, 5581–5591. doi: 10.1128/jvi.03639-14

Skalsky, R. L., Corcoran, D. L., Gottwein, E., Frank, C. L., Kang, D., Hafner, M., et al. (2012). The viral and cellular DNA targetome in lymphoblastoid cell lines. PLoS Pathog. 8:e1002484. doi: 10.1371/journal.ppat.1002484

Smith, L., Greenside, P. G., Natoli, T., Lahri, D. L., Wadden, D., and Doench, J. G. (2017). Evaluation of RNAi and CRISPR technologies by large-scale gene expression profiling in the connectivity map. PLoS Biol. 15:e2003213. doi: 10.1371/journal.pbio.2003213

Sugden, B. (2014). Epstein-Barr virus: the path from association to causality for a ubiquitous human pathogen. PLoS Biol. 12:e1001939. doi: 10.1371/journal.pbio.1001939

Tagawa, T., Albanese, M., Bovett, M., Moosmann, A., Mautner, J., Heissmeyer, V., et al. (2016). Epstein-Barr viral miRNAs inhibit antiviral CD4+ T cell responses targeting IL-12 and peptide processing. J. Exp. Med. 213, 2065–2080. doi: 10.1084/jem.20160248

Tong, J. H., Fant, X., Benoit, G., Chen, S. J., Chen, Z., and Lanotte, M. (2000). Genomic organization of the JEM-1 (BLZF1) gene on human chromosome 1q24: molecular cloning and analysis of its promoter region. Genomics 69, 380–390. doi: 10.1006/geno.2000.6347

Tse, E., and Kwong, Y. L. (2015). Epstein-Barr virus-associated lymphoproliferative diseases: the virus as a therapeutic target. Exp. Mol. Med. 47:e136. doi: 10.1038/emmm.2014.102

Vereide, D. T., Seto, E., Chiu, Y. F., Hayes, M., Tagawa, T., Grundhoff, A., et al. (2014). Epstein-Barr virus maintains lymphomas via its miRNAs. Oncogene 33, 1258–1264. doi: 10.1038/onc.2013.71

Vereide, D., and Sugden, B. (2009). Proof for EBV’s sustaining role in Burkitt’s lymphomas. Semin. Cancer Biol. 19, 389–393. doi: 10.1016/j.semcancer.2009.07.006

Wang, J., Zheng, X., Qin, Z., Wei, L., Lu, Y., Peng, Q., et al. (2019). Epstein-Barr virus miR-BART3-3p promotes tumorigenesis by regulating the senescence pathway in gastric cancer. J. Biol. Chem. 294, 4854–4866. doi: 10.1074/jbc.RA118.006853

Xu, Q., Liu, L. Z., Yin, Y., He, J., Li, Q., Qian, X., et al. (2015). Regulatory circuit of PKM2/NF-kB/miR-148a/152-modulated tumor angiogenesis and cancer progression. Oncogene 34, 5482–5493. doi: 10.1038/onc.2015.6

Yang, Y. C., Liem, A., Lambert, P. F., and Sugden, B. (2017). Dissecting the regulation of EBV’s BART miRNAs in carcinomas. Virology 505, 148–154. doi: 10.1016/j.virol.2017.02.013

Ye, J., Gradoville, L., and Miller, G. (2010). Cellular immediate-early gene expression occurs kinetically upstream of Epstein-Barr virus brf1 and brf1 following cross-linking of the B cell antigen receptor in the akata Burkitt lymphoma cell line. J. Virol. 84, 12405–12418. doi: 10.1128/jvi.01415-10

You, Y. J., Chen, Y. P., Zheng, X. X., Meltzer, S. J., and Zhang, H. (2012). aberrant methylation of the PTPRO gene in peripheral blood as a potential biomarker in esophageal squamous cell carcinoma patients. Cancer Lett. 315, 138–144. doi: 10.1016/j.canlet.2011.08.032

You, Y., Ramachandra, S. G., and Jin, T. (2020). A CRISPR-based method for testing the essentiality of a gene. Sci. Rep. 10:14779. doi: 10.1038/s41598-020-71690-8

Zhang, I., Huang, T., Zhou, Y., Cheng, A. S. L., Yu, J., Fai To, K., et al. (2018). The oncogenic role of Epstein-Barr virus-encoded microRNAs in Epstein-Barr virus-associated gastric carcinoma. J. Cell. Mol. Med. 22, 38–45. doi: 10.1111/jcmm.13354

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Yang and Sugden. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.